// App-Quantinova.ai

127 : Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial

Researchers

Presenter

  • Othman Al-Sawaf

Principal Investigators

  • Can Zhang

  • Sandra Robrecht

  • Cameron Wilson

  • Maneesh Tandon

  • Travers Ching

  • Anna-Maria Fink

  • Matthias Ritgen

  • Eugen Tausch

  • Karl-Anton Kreuzer

  • William Schary

  • Clemens-Martin Wendtner

  • Barbara Eichhorst

  • Stephan Stilgenbauer

  • Yanwen Jiang

  • Michael Hallek

  • Kirsten Fischer

Medical Centers

  • University Hospital Cologne, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf; Cologne, Cologne, Germany

  • Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Düsseldorf, German Hodgkin Study Group, Faculty of Medicine and University Hospital of Cologne,University Hospital of Cologne,Cologne,Germany

  • Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, University of Cologne, Cologne, Germany

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • Adaptive Biotechnologies, Seattle, WA

  • University Hospital Cologne, Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf; Cologne, Cologne, Germany

  • Department of General Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • AbbVie, Inc., North Chicago, IL

  • Klinikum Schwabing, Department I of Medicine, Academic Teaching Hospital of University of Munich, Munich, Germany

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • Genentech, Inc., South San Francisico, CA

  • Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University of Cologne, Cologne, Germany

Locations

  • Germany

  • United Kingdom

  • United States

Companies

  • Feng Chi Biotech Cor

  • Genentech, Inc.

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • chlorambucil

  • Venetoclax

Outcome

  • N/A

Study Design

  • Randomized

  • Adaptive

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved